SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is gaining significant attention, propelled by its AI-powered Athena platform and recent Marigold acquisition. The community is highly optimistic, discussing its perceived undervaluation and anticipating a substantial rerating as GAAP profitability nears and its leadership in AI-driven MarTech with first-party data is increasingly recognized. This positions Zeta as a key player in the evolving digital advertising landscape.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash (ZEC) is experiencing a surge of community interest driven by its robust privacy features and recent institutional endorsements. Developments like increasing shielded transaction usage, a major network upgrade, and Grayscale's push for an ETF are fueling widespread speculation about its potential as the 'better Bitcoin'.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is experiencing heightened interest as its passionate community rallies around the Injective ($INJ) ecosystem's growth, driven by recent network developments like the EVM mainnet launch and anticipated INJ ETFs. Many perceive $NONJA as a high-leverage opportunity on Injective's trajectory, emphasizing its strong community and robust liquidity as key factors for significant future gains.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending following its acquisition of Melt Pharmaceuticals and ahead of its Investor Day, where the company is expected to detail a path to significant revenue growth. Community sentiment is highly bullish, driven by anticipated Vevye market share expansion through major insurance formulary wins and speculation about short covering fueling further price momentum. Many investors believe the stock is currently undervalued, positioning it for substantial long-term gains within the ophthalmic sector.

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Sutro Biopharma is trending due to its recent reverse stock split, which helped it regain Nasdaq listing compliance, alongside a major corporate restructuring and workforce reduction. The community is actively debating the deprioritization of its lead asset, Luvelta, and the company's strategic pivot towards its next-generation ADC programs. Many investors are keenly focused on the potential for new partnerships for Luvelta and upcoming pipeline milestones, given the company's substantial cash reserves within the competitive biotech sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing a parabolic surge, primarily driven by imminent Chinese export restrictions on silver and a notable increase in industrial demand for green technology, microchips, and AI data centers. The community is fiercely debating whether this represents a historic re-pricing following decades of suppression and dwindling physical supply, or if it's an unsustainable speculative rally with bears warning of a sharp correction.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending with significant community buzz, largely fueled by its integration-ready post-quantum vault development, which positions it as a technically advanced peer-to-peer electronic cash. Amidst broader market volatility, many investors are observing BCH's remarkable resilience and discussing its potential for a major breakout, with sentiments indicating it is "extremely undervalued" and poised for substantial upside. This has fostered a strong "Hodl gang" conviction, as participants anticipate BCH's performance in a potential altcoin season.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is drawing significant attention following foundational developments, including the launch of quantum-safe state proofs, new institutional payment integrations, and a live decentralization tracker enhancing network transparency. Community discussion is split between long-term holders accumulating based on its robust technology for real-world asset adoption, and skeptics expressing concerns over recent price performance and aspects of foundation management.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MicroAlgo Inc. is trending with highly polarized sentiment, primarily driven by concerns over potential dilution and further reverse splits, while optimists highlight its undervalued position in AI and quantum technology, anticipating a significant short squeeze. The community eagerly awaits upcoming financial disclosures and monitors reported trading restrictions on certain platforms, adding to the stock's speculative nature amidst low volume.

Injective is an interoperable Layer 1 blockchain designed for DeFi applications. It provides developers with on-chain financial infrastructure modules to build dApps such as decentralized exchanges, prediction markets, and lending protocols. Its decentralized cross-chain bridging infrastructure offers compatibility with most blockchains, including EVM chains like Ethereum and non-EVM chains like Solana.

Injective

Injective is drawing attention amidst strong community discussion around its leading meme coin, $NONJA, frequently highlighted as a high-leverage play on the INJ ecosystem due to its active community and burned liquidity. This interest is amplified by news of Pineapple Financial's $100 million fundraise to acquire and stake INJ, signaling growing institutional confidence in Injective's robust financial infrastructure and deflationary tokenomics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) CEO Bassil Dahiyat sold 114,377 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.71...

Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John Desjarlais sold 73,367 shares of the company's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $15.72...

Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) CEO Bassil Dahiyat sold 114,377 shares of the business's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of...

Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has...

248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional...

Xencor Announces Extension of U.S. Patent Term on Certain Xtend Antibodies

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S...

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Xencor, Inc. (NASDAQ:XNCR - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat Ratings reports. One...

Primecap Management Co. CA Has $82.75 Million Holdings in Xencor, Inc. $XNCR

Primecap Management Co. CA lifted its holdings in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 7.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned...

Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR

Bank of Montreal Can grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 160.5% in the second quarter, according to the company in its most recent filing with the Securities and...

Xencor (NASDAQ:XNCR) Shares Up 8.7% - What's Next?

Xencor (NASDAQ:XNCR) Trading 8.7% Higher - Still a Buy...

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

XNCR
Xencor Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest XNCR News

XNCRXencor Inc